Related Experiment Video

Updated: May 22, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib in locally advanced or metastatic breast cancer

William J Gradishar1

  • 1Maggie Daley Center for Women's Cancer Care, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA. WGradishar@nmff.org

Expert Opinion on Investigational Drugs
|May 24, 2012
PubMed
Abstract

Insights

Sorafenib shows varied efficacy in advanced HER2-negative breast cancer (BC) when combined with chemotherapy. Further Phase III trials are needed to confirm its role in specific patient populations and treatment regimens.

Area of Science:

  • Oncology
  • Medical Oncology
  • Clinical Trials

Background:

  • Sorafenib is an oral multikinase inhibitor with anti-angiogenic and anti-proliferative properties.
  • Currently approved for hepatocellular and renal cell carcinomas, sorafenib is under investigation for other solid tumors, including breast cancer (BC).

Purpose of the Study:

  • To investigate the efficacy of sorafenib when added to select chemotherapies for patients with HER2-negative advanced breast cancer.
  • To evaluate the impact of sorafenib on progression-free survival (PFS) in this patient population.

Main Methods:

  • Four randomized, double-blind, placebo-controlled Phase IIb screening trials (TIES) were conducted.
  • Sorafenib was administered in combination with various chemotherapies (capecitabine, gemcitabine, paclitaxel, docetaxel, letrozole).
  • Primary endpoint for all trials was progression-free survival (PFS).

Main Results:

  • SOLTI-0701 showed significant PFS benefit with sorafenib plus capecitabine (first- or second-line).
  • AC01B07 reported a modest PFS benefit with sorafenib plus gemcitabine or capecitabine after bevacizumab progression.
  • NU07B1 and FM-B07-01 trials did not show significant PFS improvement with sorafenib combined with paclitaxel, docetaxel, or letrozole.

Conclusions:

  • Phase IIb data suggest a potential role for sorafenib in combination with specific chemotherapies for HER2-negative advanced BC.
  • Variability in results may be attributed to the chemotherapy combination used or specific patient populations.
  • Phase III confirmatory trials are essential to validate these findings and establish sorafenib's role in advanced breast cancer treatment.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...